Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Spectrum Pharmaceuticals, Inc. (SPPI)

0.443   -0.018 (-3.99%) 12-07 16:00
Open: 0.465 Pre. Close: 0.4614
High: 0.47 Low: 0.4404
Volume: 965,057 Market Cap: 90(M)

Technical analysis

as of: 2022-12-07 4:26:18 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.54     One year: 0.6
Support: Support1: 0.37    Support2: 0.31
Resistance: Resistance1: 0.46    Resistance2: 0.51
Pivot: 0.44
Moving Average: MA(5): 0.46     MA(20): 0.45
MA(100): 0.73     MA(250): 0.85
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 54.6     %D(3): 59.8
RSI: RSI(14): 46
52-week: High: 1.62  Low: 0.36
Average Vol(K): 3-Month: 3,126 (K)  10-Days: 1,643 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SPPI ] has closed above bottom band by 41.2%. Bollinger Bands are 78.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.47 - 0.47 0.47 - 0.48
Low: 0.43 - 0.44 0.44 - 0.44
Close: 0.44 - 0.44 0.44 - 0.45

Company Description

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Headline News

Wed, 07 Dec 2022
Bronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. (SPPI) Investors of Class Acti - Benzinga

Tue, 06 Dec 2022
2022-12-06 | NDAQ:SPPI | Press Release | Spectrum Pharmaceuticals Inc. - Stockhouse

Mon, 05 Dec 2022
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI - GuruFocus.com

Mon, 05 Dec 2022
Spectrum Pharmaceuticals Annou - GuruFocus.com

Mon, 28 Nov 2022
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA - Yahoo Finance

Fri, 25 Nov 2022
Health Care Sector Update for 11/25/2022: SPPI,GANX,IINN - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 203 (M)
Shares Float 161 (M)
% Held by Insiders 9.3 (%)
% Held by Institutions 26.3 (%)
Shares Short 8,510 (K)
Shares Short P.Month 6,690 (K)

Stock Financials

EPS -0.87
EPS Est Next Qtl -0.26
EPS Est This Year -1.04
EPS Est Next Year -0.75
Book Value (p.s.) 0.18
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -43.6
Return on Equity (ttm) -184.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.46
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.52
PEG Ratio 0
Price to Book value 2.46
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0.15
Forward Dividend 0
Dividend Yield 33.8%
Dividend Pay Date 2012-12-27
Ex-Dividend Date 2012-12-17
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.